Autolus Therapeutics plc
AUTL · Nasdaq · United Kingdom
Share price · AUTL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AUTL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026-6.4%
- 11 Aug 2026+12.6%
- 3 Aug 2026+22.1%
- 23 Jun 2026+11.4%
Nothing announced by AUTL that day or the session before.
- 3 Jun 2026-7.4%
Nothing announced by AUTL that day or the session before.
- 19 May 2026-9.4%
Nothing announced by AUTL that day or the session before.
- 18 May 2026+10.4%
Nothing announced by AUTL that day or the session before.
- 16 Apr 2026+8.1%
- 8 Apr 2026+9.6%
- 12 Jan 2026-17.1%
Share of unusual movement by asset
For each asset, the share of AUTL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
obecabtagene autoleucel (Aucatzyl)events and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 27% |
| Sessions with no dated event | — | 72% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
obecabtagene autoleucel(Aucatzyl) | Approved | CD19Cell therapy | Acute Lymphoblastic Leukemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
August 2028 (1)
What to watch
2029 (1)
June 2029 (1)
What to watch
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $41M | $31M | $247M+ $3.0M short-term inv. | $55M-$19M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $46M | $28M | $173M+ $30M short-term inv. | $39M-$25M operating cash flow | report ↗ |
| 2026-Q1 | $26M | $21M | $132M+ $99M short-term inv. | $72M-$65M operating cash flow | report ↗ |
| 2025-Q3 | $21M | $28M | $88M+ $281M short-term inv. | $79M-$68M operating cash flow | report ↗ |
| 2025-Q2 | $21M | $27M | $125M+ $330M short-term inv. | $48M-$73M operating cash flow | report ↗ |
| 2025-Q1 | $9.0M | $27M | $97M+ $421M short-term inv. | $70M-$76M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $40M | $659M | $82M-$77M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $37M | $707M | $58M-$51M operating cash flow | report ↗ |
| 2024-Q1 | — | $31M | $760M | $53M-$41M operating cash flow | report ↗ |
| 2023-Q3 | — | $37M | $257M | $46M-$40M operating cash flow | report ↗ |
| 2023-Q2 | — | $33M | $308M | $46M-$38M operating cash flow | report ↗ |
| 2023-Q1 | — | $27M | $343M | $40M-$42M operating cash flow | report ↗ |
| 2022-Q3 | — | $38M | $163M | $43M | report ↗ |
| 2022-Q2 | — | $31M | — | $42M | report ↗ |
| 2022-Q1 | — | $28M | — | $37M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $75M | $118M | $106M+ $197M short-term inv. | $72M-$284M operating cash flow | report ↗ |
For the full year 2025, Autolus reported revenue of $75.39M, up 645.0% YoY, with AUCATZYL net product revenue of $74.3M for the year. R&D spend was $117.69M, down 15.0% YoY, and cash and equivalents stood at $105.64M. The company posted a net loss of $287.53M and a quarterly net burn of $287.53M.
Management guided to 2026 AUCATZYL net product revenue of $120M to $135M and expects a shift to positive gross margin in 2026, with current cash expected to fund operations into Q4 2027. AUCATZYL launched in the UK after a successful NICE evaluation, and real-world ROCCA data confirmed consistent efficacy and safety. Key pipeline progress included enrollment in the pivotal Phase 2 CATULUS trial in pediatric r/r B-ALL and the LUMINA trial in lupus nephritis, with initial BOBCAT data in progressive MS and ALARIC data in AL amyloidosis expected by year-end 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $10M | $138M | $229M+ $361M short-term inv. | $55M-$206M operating cash flow | report ↗ |
| 2023-FY | — | $130M | $240M+ $0 short-term inv. | $52M-$146M operating cash flow | report ↗ |
| 2022-FY | — | $142M | $383M | $37M-$112M operating cash flow | report ↗ |
| 2021-FY | — | $135M | $311M | $36M-$118M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($16K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-02 | Piccina Cintia · U.S. CCO & Country Gen Manager | Open-market sale | 6,713 | $2.34 | $16K | Form 4 |
| 2026-09-01 | Piccina Cintia · U.S. CCO & Country Gen Manager | Option exercise | 20,000 | $2.35 | $47K | Form 4 |
| 2026-09-01 | Piccina Cintia · U.S. CCO & Country Gen Manager | Option exercise (derivative) | 20,000 | — | — | Form 4 |
| 2026-06-29 | BONNEY MICHAEL W · director | Award / grant (derivative) | 31,667 | — | — | Form 4 |
| 2026-06-29 | Azelby Robert · director | Award / grant (derivative) | 31,667 | — | — | Form 4 |
| 2026-06-29 | Bain Linda · director | Award / grant (derivative) | 31,667 | — | — | Form 4 |
| 2026-06-29 | BUTITTA CYNTHIA M · director | Award / grant (derivative) | 31,667 | — | — | Form 4 |
| 2026-06-29 | Iannone Robert · director | Award / grant (derivative) | 31,667 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 84 reporting institutions held 134.4M shares ($184.2M, 50.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MAK CAPITAL ONE LLC | 33,621,487 | $46.4M |
| 2 | Blackstone Inc. | 20,485,611 | $28.3M |
| 3 | Syncona Portfolio Ltd | 16,640,720 | $23.0M |
| 4 | ARMISTICE CAPITAL, LLC | 15,800,000 | $21.8M |
| 5 | Tetragon Partners GP Ltd | 9,500,000 | $13.1M |
| 6 | SCHRODER INVESTMENT MANAGEMENT GROUP | 9,489,345 | $12.1M |
| 7 | Frazier Life Sciences Management, L.P. | 4,447,910 | $6.1M |
| 8 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | $4.6M |
| 9 | Laurion Capital Management LP | 3,316,626 | $4.6M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 2,299,499 | $3.2M |
| 11 | BANK OF AMERICA CORP /DE/ | 1,844,671 | $2.5M |
| 12 | BlackRock, Inc. | 1,480,732 | $2.0M |
| 13 | UBS Group AG | 1,305,779 | $1.8M |
| 14 | Cetera Investment Advisers | 1,129,074 | $1.6M |
| 15 | Balyasny Asset Management L.P. | 971,691 | $1.3M |